Bayer Adds Oncology Leadership

Rebecca Jolley has been appointed senior vice president and commercial head of Oncology at Bayer, and Dr. Scott Z. Fields was named senior vice president and pharmaceutical development head, Oncology. Both are members of the Oncology Leadership Team and report to Robert LaCaze, executive vice president and head of the Oncology Strategic Business Unit.

"It is important that we stay focused on the science coupled with speed and agility to help bring important new medications and indications to patients as quickly and prudently as possible" said LaCaze. "Scott's global product development expertise combined with Rebecca's experience in successfully bringing products to market strengthens our ability to get medicines to patients." 

Previously, Ms. Jolley served as senior vice president, Americas Commercial, Oncology Business Group at Eisai, where she was responsible for leading the Oncology commercial strategy and implementation across all approved products and pipeline assets. Prior to joining Eisai, she worked at Novartis for more than two decades in a variety of roles of increasing responsibility, including sales, market access, marketing, brand leadership and general management.   

Dr. Fields joins the company from Vertex Pharmaceuticals, where he was vice president and head of Clinical Oncology and responsible for the global development of all oncology assets. Prior to Vertex, he held a number of leadership roles within the pharmaceutical industry at Smithkline Beecham, Amgen, Eisai and Arno and gained experience as a practicing oncologist in academic settings.